阿立哌唑联合抗抑郁剂治疗效果欠佳抑郁症的对照研究  

A Controlled Study of Aripiprazole Combined with Antidepressant in Treatment of Depression

作　　者：邓泓[1] 陈旭先[1] 翁赛峥[1] DENG Hong;CHEN Xuxian;WENG Saizheng(Fuzhou Neuro-psychiatric Hospital,Fuzhou 350008,China)

机构地区：[1]福州神经精神病防治院福建医科大学附属福州神经精神病医院,福建福州350008

出　　处：《中外医学研究》2018年第27期27-29,共3页CHINESE AND FOREIGN MEDICAL RESEARCH

摘　　要：目的:探讨阿立哌唑作为增效治疗对抗抑郁剂疗效欠佳的抑郁症的疗效和安全性。方法:选择经1~3次抗抑郁药规范治疗后疗效不佳的抑郁症患者100例,汉密尔顿抑郁量表(HAMD-17)总评分≥18分,随机分为研究组和对照组。研究组(50例)在原抗抑郁剂基础上联合使用阿立哌唑,对照组(50例)继续服用原抗抑郁剂,治疗时间为8周。在基线期及治疗第1、2、4、6和8周末进行量表评定,主要疗效指标为末次访视时HAMD-17项评分相对于基线的变化。结果:两组基线期及治疗后1周末HAMD-17评分比较差异无统计学意义(P>0.05);治疗后2、4、6、8周末研究组评分均低于对照组,差异均有统计学意义(P<0.05)。治疗结束时,研究组临床有效率为38.0%,缓解率为16.0%,对照组分别为12.0%、6.0%,差异均有统计学意义(P<0.05)。两组患者在治疗后第1、2、4、6、8周末TESS评分比较无统计学意义(P>0.05)。结论:阿立哌唑辅助治疗抗抑郁剂疗效欠佳抑郁症患者可有效改善抑郁症状,并提高治疗的临床有效率和缓解率。Objective：To investigate the efficacy and safety of aripiprazole as augmentation for major depressive disorder （MDD） with inadequate response to antidepressants.Method： A total of 100 adults with MDD and inadequate response to 1 to 3 antidepressant therapy,the Hamilton Depression Scale （HAMD-17） total score ≥18 were randomly divided into research group and control group.The research group （50 cases） accepted aripiprazole treatment with the original antidepressant,and the control group （50 cases） continued to take the original antidepressant,the treatment time was 8 weeks.Scales were assessed at baseline and at week 1, 2, 4, 6 and 8.The primary efficacy measurement was the change of HAMD-17 total score from baseline to the end of study.Result： There was no significant difference in HAMD-17 scores between the two groups in baseline period and 1 week after treatment （P〉0.05）,and the scores in study group at the end of 2,4,6,8 weeks after treatment were lower than those in the control group （P〈0.05）.At the end of the treatment, the clinical effective rate was 38.0 and the remission rate was 16.0 in the study group,and 12.0 and 6.0 in the control group,respectively （P〈0.05）.There was no significant difference in TESS scores between the two groups at the end of 1 week and 2,4,6,8 weeks （P〉0.05）.Conclusion：Aripiprazole as augmentation for MDD with inadequate response to antidepressants can effectively improve depressive symptoms,and improve the response and remission rates of treatment.

关 键 词：阿立哌唑 抑郁症 增效剂 

分 类 号：R749.4[医药卫生—神经病学与精神病学]